The opioid epidemic in the United States has led to a sharp rise in overdose deaths over the past two decades. Although some progress was observed prior to the coronavirus disease 2019 pandemic, opioid-related mortality has increased again in recent years, underscoring the need to re-examine national trends. A retrospective analysis of opioid overdose mortality among US adults aged 25 years and older from 1999 to 2024 was performed using data from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiological Research (CDC WONDER) Multiple Cause-of-Death database. Opioid-related deaths were identified using the International Classification of Diseases, Tenth Revision, codes T40.0–T40.4 and T40.6. Mortality rates were calculated by year, sex, age, race/ethnicity, and US census region. Temporal trends were evaluated using Joinpoint regression to estimate annual percent changes. A total of 806,765 opioid overdose deaths occurred during the study period. The age-adjusted mortality rate (AAMR) increased from 4.41 to 22.84 per 100,000. Men consistently had higher AAMRs than women (men: 20.64; women: 9.52). Racial disparities were evident, with the highest rates observed among non-Hispanic American Indian/Alaska Native (21.79), non-Hispanic White (18.07), and non-Hispanic Black (15.97) populations. Adults aged 35–44 years had the highest crude mortality rates (20.52). Among US regions, the Northeast had the highest AAMR (18.09), followed by the Midwest (15.69), South (14.74), and West (13.09). These findings confirm that opioid overdose remains a major public health issue, with persistent demographic and regional disparities necessitating targeted strategies to reduce mortality.
GomesT, LedlieS, TadrousM, MamdaniM, PatersonJM, JuurlinkDN. Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 pandemic, 2011–2021. JAMA Netw Open, 2023; 6(7):e2322303; doi: 10.1001/jamanetworkopen.2023.22303
SinghGK, KimIE, GirmayM, et al.Opioid Epidemic in the United States: Empirical trends, and a literature review of social determinants and epidemiological, pain management, and treatment patterns. Int J MCH AIDS, 2019; 8(2):89–100; doi: 10.21106/ijma.284
4.
KlineD, HeplerSA, KrawczykN, Rivera-AguirreA, WallerLA, CerdáM. A state-level history of opioid overdose deaths in the United States: 1999–2021. PLoS One, 2024; 19(9):e0309938; doi: 10.1371/journal.pone.0309938
5.
FlorenceC, LuoF, RiceK. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend, 2021; 218:108350; doi: 10.1016/j.drugalcdep.2020.108350
6.
ComptonWM, JonesCM. Epidemiology of the U.S. opioid crisis: The importance of the vector. Ann N Y Acad Sci, 2019; 1451(1):130–143; doi: 10.1111/nyas.14209
7.
National Academies of Sciences, Engineering, and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. In: Evidence on strategies for addressing the opioid epidemic. National Academies Press; Washington, DC; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK458653/
8.
von ElmE, AltmanDG, EggerM, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol, 2008; 61(4):344–349; doi: 10.1016/j.jclinepi.2007.11.008
9.
SlavovaS, QuesinberryD, CostichJF, et al.ICD-10-CM-based definitions for emergency department opioid poisoning surveillance: Electronic health record case confirmation study. Public Health Rep, 2020; 135(2):262–269; doi: 10.1177/0033354920904087
10.
KolodnyA, CourtwrightDT, HwangCS, et al.The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction. Annu Rev Public Health, 2015; 36:559–574; doi: 10.1146/annurev-publhealth-031914-122957
11.
CiceroTJ, EllisMS, SurrattHL, KurtzSP. The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry, 2014; 71(7):821–826; doi: 10.1001/jamapsychiatry.2014.366
12.
O’DonnellML, SchaeferI, VarkerT, et al.A systematic review of person-centered approaches to investigating patterns of trauma exposure. Clin Psychol Rev, 2017; 57:208–225; doi: 10.1016/j.cpr.2017.08.009
13.
CookRR, FootC, ArahOA, et al.Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addict Sci Clin Pract, 2023; 18(1):11; doi: 10.1186/s13722-023-00364-3
14.
GhoseR, ForatiAM, MantschJR. Impact of the COVID-19 pandemic on opioid overdose deaths: A spatiotemporal analysis. J Urban Health, 2022; 99(2):316–327; doi: 10.1007/s11524-022-00610-0
15.
JemberieWB, Stewart WilliamsJ, ErikssonM, et al.Substance use disorders and COVID-19: Multi-faceted problems which require multi-pronged solutions. Front Psychiatry, 2020; 11:714; doi: 10.3389/fpsyt.2020.00714
16.
SilvaMJ, KellyZ. The escalation of the opioid epidemic due to COVID-19 and resulting lessons about treatment alternatives. Am J Manag Care, 2020; 26(7):e202–e204; doi: 10.37765/ajmc.2020.43386
17.
National Institute on Drug Abuse. National Institute on Drug Abuse. Available from: https://nida.nih.gov/ [Last accessed: July29, 2025].
18.
MasonM, SolimanR, KimHS, PostLA. Disparities by sex and race and ethnicity in death rates due to opioid overdose among adults 55 years or older, 1999 to 2019. JAMA Netw Open, 2022; 5(1):e2142982; doi: 10.1001/jamanetworkopen.2021.42982
19.
Centers for Disease Control and Prevention. Products—Vital Statistics Rapid Release: Provisional Drug Overdose Data. Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm [Last accessed July29, 2025].
BhaiM, McMichaelBJ, MitchellDT. Impact of fentanyl test strips as harm reduction for drug-related mortality. Med Care Res Rev, 2025; 82(3):240–251; doi: 10.1177/10775587251316919
23.
KnudsenHK, HartmanJ, WalshSL. The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States. Drug Alcohol Depend, 2022; 232:109336; doi: 10.1016/j.drugalcdep.2022.109336
24.
WenH, SoniA, HollingsworthA, et al.Association between Medicaid expansion and rates of opioid-related hospital use. JAMA Intern Med, 2020; 180(5):753–759; doi: 10.1001/jamainternmed.2020.0473
25.
Centers for Disease Control and Prevention. US overdose deaths decrease almost 27% in 2024. Centers for Disease Control and Prevention, National Center for Health Statistics Pressroom; 2025. Available from: https://www.cdc.gov/nchs/pressroom/releases/20250514.html
26.
WarneD, FrizzellLB. American Indian health policy: Historical trends and contemporary issues. Am J Public Health, 2014; 104,(Suppl 3):S263–S267; doi: 10.2105/AJPH.2013.301682
27.
JimMA, AriasE, SenecaDS, et al.Racial misclassification of American Indians and Alaska natives by Indian Health service contract health service delivery area. Am J Public Health, 2014; 104(Suppl 3):S295–S302; doi: 10.2105/AJPH.2014.301933
28.
PostLA, CiccaroneD, UnickGJ, et al.Decline in US drug overdose deaths by region, substance, and demographics. JAMA Netw Open, 2025; 8(6):e2514997; doi: 10.1001/jamanetworkopen.2025.14997
29.
ChhabraN, SmithD, DickinsonG, et al.Trends and disparities in initiation of buprenorphine in US Emergency Departments, 2013–2022. JAMA Netw Open, 2024; 7(9):e2435603; doi: 10.1001/jamanetworkopen.2024.35603
30.
TanzLJ, StewartA, GladdenRM, KoJY, OwensL, O’DonnellJ. Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths—United States, 2021–2024. MMWR Morb Mortal Wkly Rep, 2024; 73(48):1099–1105; doi: 10.15585/mmwr.mm7348a2
31.
LimTY, DongH, StringfellowE, et al.Temporal and spatial trends of fentanyl co-occurrence in the illicit drug supply in the United States: A serial cross-sectional analysis. Lancet Reg Health Am, 2024; 39:100898; doi: 10.1016/j.lana.2024.100898
32.
RuddRA, SethP, DavidF, SchollL. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep, 2016; 65(50–51):1445–1452; doi: 10.15585/mmwr.mm655051e1
33.
MattsonCL, TanzLJ, QuinnK, KariisaM, PatelP, DavisNL. Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep, 2021; 70(6):202–207; doi: 10.15585/mmwr.mm7006a4
34.
DowellD, NoonanRK, HouryD. Underlying factors in drug overdose deaths. JAMA, 2017; 318(23):2295–2296; doi: 10.1001/jama.2017.15971
35.
AltekruseSF, CosgroveCM, AltekruseWC, JenkinsRA, BlancoC. Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC). PLoS One, 2020; 15(1):e0227966; doi: 10.1371/journal.pone.0227966
36.
National Academies of Sciences, Engineering, and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. In: Trends in opioid use, harms, and treatment. National Academies Press: Washington, DC; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK458661/
37.
ButelmanER, HuangY, EpsteinDH, et al.Overdose mortality rates for opioids and stimulant drugs are substantially higher in men than in women: State-level analysis. Neuropsychopharmacology, 2023; 48(11):1639–1647; doi: 10.1038/s41386-023-01601-8
ChatmonBN. Males and mental health stigma. Am J Mens Health, 2020; 14(4):1557988320949322; doi: 10.1177/1557988320949322
40.
SharpJL, PearsonT, SmithMA. Sex differences in opioid receptor mediated effects: Role of androgens. Neurosci Biobehav Rev, 2022; 134:104522; doi: 10.1016/j.neubiorev.2022.104522
